Terumo Neuro (formerly MicroVention) has launched the SOFIA 88 Neurovascular Support Catheter commercially in the US, making a new addition to its stroke portfolio.
The large-bore catheter is designed for procedural flexibility, providing physicians with control during interventions.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Terumo Neuro noted that the launch of the catheter builds on the SOFIA Catheter line legacy, which has been used in over 500,000 procedures in 170 nations over the last ten years.
This new catheter claims to provide a 0.088in inner diameter with engineering enhancements.
It provides trackability through anatomy with optimised transition zones and a soft atraumatic distal tip.
Additionally, the catheter offers proximal stability to facilitate ease of use with short and long sheaths and provides flexibility along the complete work length to minimise vessel trauma and facilitate easy navigation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCompatible with the SOFIA Flow Plus 6F Aspiration Catheter, the SOFIA 88 integrates into current aspiration strategies.
According to the company, clinical evidence from the SOFAST registry has shown robust outcomes for the SOFIA Flow Plus 6F in terms of efficacy, speed, safety, and overall clinical outcomes.
The SOFIA 88 catheter complements Terumo Neuro’s comprehensive stroke solution portfolio, which includes aspiration catheters, the ERIC retrieval device, the BOBBY balloon guide catheter, the WEDGE microcatheter, the HEADWAY microcatheters and the TRAXCESS guidewires.
Terumo Neuro CEO and president Carsten Schroeder said: “As we introduce the SOFIA 88 neurovascular support catheter, we are building on a decade of performance that physicians around the world have come to trust.
“This launch reflects our continued investment in neurovascular innovation, made possible through direct collaboration with physicians and our strong research and development (R&D) and manufacturing capabilities. Together, we are delivering meaningful advancements in stroke care designed to improve outcomes for patients worldwide.”
